

# SCIENTIFIC REPORTS



OPEN

## A non-invasive magnetic resonance imaging approach for assessment of real-time microcirculation dynamics

Tameshwar Ganesh<sup>1,2</sup>, Marvin Estrada<sup>3</sup>, Herman Yeger<sup>4,5</sup>, James Duffin<sup>6</sup> & Hai-Ling Margaret Cheng<sup>1,2,7,8,9</sup> 

We present a novel, non-invasive magnetic resonance imaging (MRI) technique to assess real-time dynamic vasomodulation of the microvascular bed. Unlike existing perfusion imaging techniques, our method is sensitive only to blood volume and not flow velocity. Using graded gas challenges and a long-life, blood-pool  $T_1$ -reducing agent gadofosveset, we can sensitively assess microvascular volume response in the liver, kidney cortex, and paraspinal muscle to vasoactive stimuli (i.e. hypercapnia, hypoxia, and hypercapnic hypoxia). Healthy adult rats were imaged on a 3 Tesla scanner and cycled through 10-minute gas intervals to elicit vasoconstriction followed by vasodilatation. Quantitative  $T_1$  relaxation time mapping was performed dynamically; heart rate and blood oxygen saturation were continuously monitored. Laser Doppler perfusion measurements confirmed MRI findings: dynamic changes in  $T_1$  corresponded with perfusion changes to graded gas challenges. Our new technique uncovered differential microvascular response to gas stimuli in different organs: for example, mild hypercapnia vasodilates the kidney cortex but constricts muscle vasculature. Finally, we present a gas challenge protocol that produces a consistent vasoactive response and can be used to assess vasomodulatory capacity. Our imaging approach to monitor real-time vasomodulation may be extended to other imaging modalities and is valuable for investigating diseases where microvascular health is compromised.

Measuring pathological alteration in local blood volume and flow is a diagnostic imaging mainstay best known for cancer detection and diagnosis. Imaging tumor microvascular changes, namely, increased vascularity and poor perfusion, is achieved using contrast-enhanced techniques, where a tracer is administered intravenously and its accumulation and distribution determined to distinguish the tumor from surrounding normal tissue. Contrast-enhanced imaging also benefits the diagnosis of a variety of other medical conditions that involve changes in local blood perfusion, such as myocardial infarction<sup>1</sup>, stroke<sup>2</sup>, Alzheimer's<sup>3,4</sup>, and diabetes<sup>5</sup>. The underlying microvascular pathology differs in these conditions (e.g. upstream obstruction, changes in the capillary wall ultrastructure<sup>2,3,6-8</sup>, etc.) from the oncology context, but the utility of contrast-enhanced imaging remains since the changes in local blood volume and/or flow are permanent. For this reason, conventional contrast-enhanced imaging suffices even though it provides only a *static* snapshot of microvascular function.

A completely different concept to conventional static imaging of microvessel function is imaging their *functional dynamics*. That is, we temporally monitor how blood vessels respond to changing metabolic and physical demands, which cannot be captured with a static measurement at a single time-point. This diagnostic capability is important when ultrastructural or neuronal deficits that compromise vasomodulation are present, but where

<sup>1</sup>Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. <sup>2</sup>Translational Biology & Engineering Program, Ted Rogers Centre for Heart Research, Toronto, Canada. <sup>3</sup>Lab Animal Services, Hospital for Sick Children, Toronto, Canada. <sup>4</sup>Developmental & Stem Cell Biology, Hospital for Sick Children Research Institute, Toronto, Canada. <sup>5</sup>Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Canada. <sup>6</sup>Department of Anesthesia, University of Toronto, Toronto, Canada. <sup>7</sup>Translational Medicine, Hospital for Sick Children Research Institute, Toronto, Canada. <sup>8</sup>The Edward S. Rogers Sr. Department of Electrical & Computer Engineering, University of Toronto, Toronto, Canada. <sup>9</sup>Institute of Biomaterials & Biomedical Engineering, University of Toronto, Toronto, Canada. Correspondence and requests for materials should be addressed to H.-L.C. (email: [hailing.cheng@utoronto.ca](mailto:hailing.cheng@utoronto.ca))

overt changes in blood volume or flow have not yet manifested. A simple example of this concept is the cardiac stress test, where perfusion differences between normal and ischemic myocardium are highlighted when the subject performs exercise, whereas at rest there may be no perfusion differences detectable. By employing two time points for comparison, before and after exercise, the stress test allows us to assess the capacity for *response*.

The ideal assessment of microvessel functional dynamics involves repeated measurements at multiple time-points. There are two classes of techniques currently available to achieve this goal: focal and whole organ assessment. Focal techniques are restricted to skin applications and include: laser Doppler fluxmetry of blood flow<sup>9,10</sup>, transcutaneous oxygen tension<sup>11</sup>, and iontophoresis<sup>12</sup>, which delivers vasoactive agents sub-dermally and measures blood flow using laser-based methods<sup>13</sup>. Whole organ approaches address the limited penetration depth associated with focal techniques. Examples in this category include: electron-beam computed tomography (CT)<sup>14</sup>, magnetic resonance imaging (MRI)<sup>15</sup>, and intravascular Doppler ultrasound<sup>16</sup>, which are used to assess blood volume changes in response to vasoactive agents such as acetylcholine and nitroprusside. However, these methods are fraught with several significant limitations. For example, vasoactive agents have been shown to generate large intra-subject variability<sup>17</sup>, and prolonged and/or repeated infusions may lead to tachyphylaxis<sup>18</sup>. To date, a non-invasive 3D technique does not exist for the assessment of microvascular functional dynamics in whole organs deep in the body.

In this paper, we propose a novel 3D MRI-based technique for the assessment of microvascular functional dynamics by measuring in near real-time blood volume changes in whole organs *in vivo*, addressing the main limitations of existing methods. Our technique employs a vasoactive stimulus in the form of air with altered levels of carbon dioxide (CO<sub>2</sub>) and oxygen (O<sub>2</sub>). Inhaling elevated CO<sub>2</sub> levels (hypercapnia) and lowered O<sub>2</sub> levels (hypoxia) stimulates changes in blood volume in normal physiology, and measuring such changes can assess vascular tone modulatory capacity in response to stress. Unlike pharmacological agents, the use of CO<sub>2</sub> and O<sub>2</sub> is not associated with adverse side effects or with prolonged monitoring time<sup>19</sup>. In fact, moderate hypercapnia with end-tidal CO<sub>2</sub> (P<sub>ETCO<sub>2</sub></sub>) ranging between 40 and 50 mmHg<sup>20</sup> and moderate hypoxia with end-tidal O<sub>2</sub> (P<sub>ETO<sub>2</sub></sub>) up to 45 mmHg<sup>21–23</sup> have been shown to be well tolerated in humans, and at these levels, blood volume can be modulated in extracranial tissues<sup>24–28</sup>. A second critical aspect of our approach is the use of a stable, long-life blood-pool agent (gadofosveset) to allow accurate assessment of blood volume changes that occur dynamically over the course of minutes. The proposed MRI technique demonstrates, for the first time, a new surgically non-invasive 3D imaging capability to visualize and assess microvascular response, specifically microvascular blood volume changes, to transient gas stimuli in abdominal organs, using a time scale consistent with physiological dynamics.

## Methods

**Controlled Gas Delivery Setup and Animal Monitoring.** A controlled gas mixing circuit was built for the purpose of delivering graded levels of CO<sub>2</sub> and O<sub>2</sub>, and animals were mechanically ventilated to allow control over the rate and depth of breathing. The system consisted of a computer-controlled GSM-3 gas mixer (CWE Inc., Ardmore, PA, USA) to blend the desired gas mixture at a constant total flow rate of 5 L/min. The resulting gas mixture was fed first into an isoflurane vaporiser (2 L/min) and then into an MRI compatible ventilator (MRI-1 Ventilator; CWE, Ardmore, PA, USA). Vital signs (heart rate, blood oxygen saturation) of the animal were monitored and recorded using a rodent oximeter and physiological monitor (MouseOX Plus; STARR Life Sciences) mounted on the hindpaw. These physiological measurements were taken in real-time to ensure we could monitor the animal's status and provide an indication on what gas challenge levels were safe.

**Animal Preparation.** This study was approved by the Lab Animal Services animal care committee at the Hospital for Sick Children (protocol #22500), and all procedures were conducted in accordance with the Canadian Council on Animal Care. Female adult Sprague Dawley rats ( $N = 21$ ) (Charles River Laboratories) weighing 250–300 g were used for this study. The animal was anesthetized on 5% isoflurane in room air (2 L/min flow rate of isoflurane, Forene, Abbott Labs, Baar, Switzerland) and then administered a series of gas challenges as previously described by Ganesh *et al.*<sup>24</sup>. Briefly, they were first anesthetized in an induction chamber and then placed supine on an inclined plane and intubated with a 14-gauge angiocatheter. For the fourteen animals on which MRI was performed, the animal was transferred supine immediately after intubation to the imaging coil, resting on a water blanket maintained at 38 °C (HTP-1500, Adroit Medical Systems, Loudon, TN). The endotracheal tube was connected to the flexible tubing from the gas delivery system, and the animal was ventilated at a rate of 65 to 70 breaths per minute, adjusted to maintain arterial blood gases within physiological limits. The chest region was observed for a rise-and-fall motion consistent with proper respiration. The sensors of the oximeter were then clipped on the hindpaw. The animal was maintained for the duration of the imaging experiment on 2% isoflurane in room air or different gas mixtures at a flow rate of 1 L/min.

***In-vivo* MRI.** Imaging was performed on a 3-Tesla clinical scanner (Achieva 3.0 T TX, Philips Medical Systems, Best, The Netherlands), using an 8-channel wrist coil for signal detection. Rats were placed supine, feet first within the coil. The heart rate and blood oxygen saturation were continuously monitored using the pulse oximeter. Localizer scans were first acquired to determine placement of the imaging volume on the thoracic-abdominal region. Coronal imaging slices were positioned to encompass the kidney, liver, and paraspinous muscle.

To determine the time interval over which contrast enhancement in blood remained fairly stable,  $T_1$ -maps were acquired every 20 minutes after administering gadofosveset (trade names Vasovist, Ablavar) via the tail vein at a dose of 0.3 mmol/kg. Two animals were used to determine the contrast profile while they were maintained on room air (no gas challenge).  $T_1$  mapping was performed using a variable flip-angle approach<sup>29</sup> on a 3D spoiled-gradient echo acquisition: repeated at flip angles of 2°, 10°, and 20°; other parameters were repetition time

(TR) = 6.13 ms, echo time (TE) = 3.2 ms, number of signal averages (NSA) = 8, 100 mm field-of-view (FOV), twenty-two 1-mm thick slices, and  $0.6 \times 0.6$  mm in-plane resolution, acquisition time ~6 min.

Gas challenge experiments were performed by placing animals initially on room air and acquiring a baseline anatomical 3D  $T_1$ -weighted spoiled-gradient echo sequence with fat suppression: TR = 3.73 ms, TE = 1.85 ms, flip angle =  $20^\circ$ , NSA = 3, 100 mm FOV, ten 3-mm thick slices, and  $0.7 \times 0.7$  mm in-plane resolution, acquisition time = 31.4 s. Pre-injection  $T_1$  mapping was again performed to enable calculation of post-injection  $T_1$  relaxation times via the gradient echo signal equation<sup>30</sup>. Gadofosveset (0.3 mmol/kg) was then administered via the tail vein, and 8–12 minute-duration gas challenges beginning with normoxia (21%  $O_2$ ) were sequentially applied. Four different types of challenge were studied: extreme hypercapnia (20%  $CO_2$ ), mild hypercapnia (2–5%  $CO_2$ ), hypoxia (12%  $O_2$ ), and hypercapnic hypoxia (20%  $CO_2$  + 12%  $O_2$ ). Four animals were used to study each level of gas stimulus (exceptions are indicated in figure captions). The 3D  $T_1$ -weighted sequence was repeated every 2 minutes throughout the session for a total duration of at most 40 minutes after contrast administration.

**Data Analysis.** MRI data was transferred to an independent workstation for data analysis using Matlab (v.8.3) (MathWorks, Natick, MA).  $T_1$ -maps were computed as described previously<sup>29</sup>. In the absence of gas challenge, changes in post-contrast  $T_1$  were determined from  $T_1$ -maps in regions of interest (ROIs) outlined in the kidney cortex, liver, and paraspinal muscle and in the descending aorta close to the bifurcation to the iliacs to minimize flow-related effects for blood  $T_1$  quantification. To study microvascular response to gas challenge,  $T_1$  relaxation times were calculated from the post-contrast signal intensity and pre-contrast  $T_1$  via the gradient echo signal equation. The mean  $T_1$  relaxation time was calculated at all time-points across different gas challenge episodes in ROIs encompassing the liver parenchyma, kidney cortex, and paraspinal muscle at their largest cross-section.

**Statistical Analysis.** Changes in the mean  $T_1$  relaxation time were then analysed to determine if significant changes from baseline (normoxia) occurred and if gas challenge-specific patterns existed in different organs. Changes in  $T_1$  were investigated using one-way analysis of variance (ANOVA), with the main effect being the gas challenge. Post-hoc Tukey-Kramer testing was then performed at the 95% confidence level. Significance is reported at a  $p$ -value of 5% unless otherwise stated.

Heart rate and blood oxygen saturation measurements from the mouse oximeter were also compared using ANOVA. A one-way analysis was performed, with the main effect being the gas challenge. Significance is reported at a  $p$ -value of 5%.

**Laser Doppler Perfusion Measurements.** Real-time measurements of relative tissue perfusion were obtained in the liver and kidney cortex to validate the changes observed on MRI. Seven rats were used on four different gas inhalation protocols. The OxyFlo (Oxford Optronix Ltd., Oxford, UK) fiber-optic system was used to provide minimally invasive (using fiber optic probes 250–450 microns in diameter) real-time monitoring of tissue perfusion. The OxyFlo system uses laser Doppler flowmetry to provide continuous monitoring of blood flow in relative perfusion units (BPU). The BPU is useful for assessing relative perfusion changes in an organ but should not be used to compare different tissue types, which tend to differ in their optical properties.

To perform invasive perfusion measurements, a laparotomy was performed to expose the liver and kidney while the animal was anesthetized on isoflurane, and the exposed organs were covered with wet gauze to maintain hydration. One Oxyflo channel was used to monitor perfusion from a probe inserted between liver lobes, and a second channel was used to monitor perfusion from a probe inserted under the renal capsule to measure perfusion in the kidney cortex. These probe placement strategies were chosen to avoid puncturing the liver and causing bleeding and to ensure kidney measurements were made in the cortex and not in the medulla. To mitigate effects of respiratory motion on the liver, the probes were sutured to the skin such that the probes would follow the motion of the respiratory cycle.


**Data Availability Statement.** The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

## Results


Figure 1 shows the time-course change in  $T_1$  relaxation time post-gadofosveset injection in blood, liver, kidney cortex, and paraspinal muscle in the absence of gas challenge. Although gadofosveset has a slower renal elimination rate than non-blood-pool agents, it is clear from Fig. 1 that  $T_1$  increases steadily in all tissue types as the  $T_1$ -reducing agent is slowly excreted from the body. We chose to limit our “stable” window of investigation to the first 40 minutes post-injection where the  $T_1$  fluctuation in blood was less than double the baseline  $T_1$  value.

Examples of changes on  $T_1$ -weighted images and in  $T_1$  relaxation times for three gas challenge protocols are shown in Figs 2–4. Note that bright signal on  $T_1$ -weighted images is associated with a low  $T_1$  relaxation time. Images shown were acquired at the end of the gas challenges indicated (subfigures A to D), and the corresponding time-course change in  $T_1$  for each protocol is also shown (subfigure E). Figure 2 illustrates our ability to visualize the evolving vasoconstriction effected by hypercapnia and hypercapnic hypoxia, which is particularly pronounced in the kidney cortex where the signal decreased dramatically upon hypercapnia and was further sustained with hypercapnic hypoxia. Mild hypercapnia (5%  $CO_2$ ) brought about elevated signal consistent with vasodilatation, as expected. Figure 3 illustrates the differential vasoconstrictory effects of hypoxia and hypercapnia, and it is seen that hypercapnia induces greater vasoconstriction than does hypoxia, with the largest change observed for both stimuli combined. Figure 4 illustrates the blunting effect of mild hypercapnia on successive severe hypercapnic stimuli. Except for the scenario shown Fig. 4, changes were much milder in the liver and paraspinal muscle.

Figure 5 summarizes across all animals the changes in  $T_1$  relaxation times for different gas challenge transitions, starting from different baseline gases. An increase in  $T_1$  was observed in all tissues upon transition from normal air to severe hypercapnia or hypoxia or both – kidney cortex (24% to 50% increase), liver (15% to 22%



**Figure 1.** Stability of the blood-pool agent gadofosveset in the microvascular bed. Temporal evolution of mean  $T_1$  relaxation times and standard error in the aorta, liver, kidney, and paraspinal muscle post-administration of gadofosveset in the absence of gas challenge stimuli ( $N = 2$ ).




**Figure 2.** Dynamic MR imaging of hypercapnia- and hypercapnic hypoxia-mediated vasomotion. The kidney is shown on  $T_1$ -weighted images acquired at the end of successive 8–12 minute gas challenges in a rat subjected to the following sequence: normoxia (A) → hypercapnia (20%  $\text{CO}_2$ ) (B) → hypercapnic hypoxia (20%  $\text{CO}_2$  + 12%  $\text{O}_2$ ) (C) → hypercapnia (5%  $\text{CO}_2$ ) (D). Corresponding temporal evolution of changes in  $T_1$  relaxation times in the liver, kidney, and paraspinal muscle (E).


increase), and paraspinal muscle (9% to 16% increase). The trends in  $T_1$  are consistent with greater vasoconstriction in going from hypoxia to hypercapnia and finally hypercapnic hypoxia. Only 2%  $\text{CO}_2$  showed no significant change from baseline air, but 5%  $\text{CO}_2$  produced a marked decrease in  $T_1$  suggestive of vasodilatation. When starting from either a hypercapnic (20%  $\text{CO}_2$ ) or hypercapnic hypoxic baseline, a trend toward decreased  $T_1$  was observed for 12%  $\text{O}_2$  and 5%  $\text{CO}_2$  in the kidney cortex, suggestive of vasodilatation that is expected to occur. Transitions from a hypoxic baseline produced changes consistent with the lower vasoconstrictory effect of hypoxia compared to hypercapnia.

Pulse oximeter measurements of heart rate and blood oxygen saturation for all gas challenge transitions are shown in Fig. 6. Starting from normal air, heart rate increased for 20%  $\text{CO}_2$  (25% increase) and hypercapnic hypoxia (30% increase) but decreased for hypoxia (19% decrease) and mild hypercapnia (10% decrease). Blood oxygen saturation decreased for all hypercapnic and hypoxic challenges, except for 2%  $\text{CO}_2$ . Starting from either 20%  $\text{CO}_2$  or a hypercapnic hypoxic baseline, heart rate decreased only upon transitioning to less stressful challenges (hypoxia and 5%  $\text{CO}_2$ ), and blood oxygen increased only on transitioning to 5%  $\text{CO}_2$ . Starting from a hypoxic baseline, both heart rate and blood oxygen saturation increased when moving to strictly hypercapnic challenges. Significant increases in heart rate were obtained on transitioning from an isocapnic baseline to hypercapnic hypoxia.

Figure 7 illustrates the relative change in laser Doppler-measured blood perfusion in the liver and kidney cortex for different gas challenges, again starting from different baseline gases. Perfusion increased substantially in both organs on transition from normal air to mild hypercapnia but decreased for hypoxic and more extreme hypercapnic challenges. In general, the magnitude of perfusion changes in the liver was smaller compared to the kidney cortex, a trend consistent with MRI observations.



**Figure 3.** Dynamic MR imaging of differential microvascular response to hypercapnia and hypoxia. The kidney is shown on  $T_1$ -weighted images acquired at the end of successive 8–12 minute gas challenges in a rat subjected to the following sequence: normoxia (A) → hypoxia (12% O<sub>2</sub>) (B) → hypercapnia (20% CO<sub>2</sub>) (C) → hypoxic hypercapnia (12% O<sub>2</sub> + 20% CO<sub>2</sub>) (D). Corresponding temporal evolution of changes in  $T_1$  relaxation times in the liver, kidney, and paraspinal muscle (E).




**Figure 4.** Dynamic MR imaging of blunting effect of mild hypercapnia-mediated vasodilatation on subsequent vasoconstriction capacity. The kidney is shown on  $T_1$ -weighted images acquired at the end of successive 8–12 minute gas challenges in a rat subjected to the following sequence: normoxia (A) → mild hypercapnia (5% CO<sub>2</sub>) (B) → severe hypercapnia (20% CO<sub>2</sub>) (C) → hypoxic hypercapnia (12% O<sub>2</sub> + 20% CO<sub>2</sub>) (D). Corresponding temporal evolution of changes in  $T_1$  relaxation times in the liver, kidney, and paraspinal muscle (E).

A sample real-time perfusion recording obtained from laser Doppler measurements is shown in Fig. 8 for both the kidney cortex and the liver. The decrease in perfusion observed on transition to 20% CO<sub>2</sub> and further decrease on transition to hypercapnic hypoxia, is analogous to similar signal decreases on MRI (see Fig. 2). Likewise, mild increases in perfusion on the transition to 5% CO<sub>2</sub> correlates with increased signal on MRI. These gold-standard perfusion measurements support the interpretation of increasing and decreasing signal intensity as indicators of vasodilatation and vasoconstriction, respectively.

## Discussion

Microvascular dysfunction (i.e. compromised capacity to adjust microvascular blood volume) is at the heart of a variety of pathologies ranging from stroke<sup>31</sup> to diabetes<sup>32</sup>. The approach of most current diagnostics is measurement of blood volume changes pre- and post-administration of pharmacological agents that alter vascular tone. Most applications to date have been limited primarily to the skin, but some groups have attempted to probe deeper organs using non-invasive techniques such as CT<sup>33</sup>, positron emission tomography (PET)<sup>34</sup>, ultrasound<sup>35</sup>, and MRI. These methods are also limited in terms of radiation burden (CT and PET), low spatial resolution (PET and ultrasound<sup>36</sup>), and reliance on pharmacological interventions that carry significant risks of side effects. The




**Figure 5.** MRI response to gas challenges. Mean changes in  $T_1$  relaxation times for different gas challenge regimes averaged across all animals ( $N = 4$  per group) and standard error are shown for the liver, kidney cortex, and paraspinal muscle. Exception is 2% CO<sub>2</sub>, which was studied in a single animal. Significant differences from baseline challenges are indicated (\* $P < 0.05$ ).

use of MRI to assess microvascular volume dynamics has been limited, with the earliest MRI attempts using solely a non-pharmacological stimulus, hypercapnia, to modulate vasoactive tone<sup>37</sup>, and subsequent studies adding in an extracellular contrast agent in an attempt to monitor changes in blood volume<sup>25</sup>. Yet, due to the short life time of the contrast agent in blood, accurate assessment of vasomodulation was not possible.

In this study, we present a non-invasive technology for 3D assessment of dynamic response in microvascular blood volume deep in the body. Our approach has a unique combination of critically important novel features. The first feature is an optimized gas challenge protocol that will *consistently* elicit vasoconstriction followed by vasodilatation. This protocol was designed after thorough testing of the body's physiological response to different gases and the order of delivery. The second important feature is the use of a stable, long-life blood-pool  $T_1$ -reducing agent, gadofosveset, to address two important limitations of traditional vasoreactivity assessment<sup>25</sup>, which is confounded by blood oxygen or flow effects. By introducing contrast and using  $T_1$ -weighted imaging, we sensitize the acquisition to microvascular blood volume and remove any confounding influence from blood oxygen level. Also, the relatively stable enhancement profile of a blood-pool agent versus an extravascular agent provides a constant baseline over an intended time interval; this window is essential to applying gas challenges that must be sustained long enough to produce a vasomodulatory effect and to ensuring that any signal change occurring over that interval is primarily due to changes in microvessel volume and not contrast elimination. It is important to note that while blood-pool agents have been used for quantifying *static* blood volume<sup>38</sup>, its application to capture vasomodulation has never been reported.

In interpreting the observed MRI responses, we shall also revisit known underlying physiological responses to gas challenges where appropriate.

Systemically, hypercapnia has a significant impact on the cardiovascular and respiratory systems. An important consequence of hypercapnia is respiratory acidosis, which reduces left ventricle contractility and stroke volume<sup>39,40</sup> but is compensated for by an increased heart rate<sup>40</sup>. This response explains the 25% increase in heart rate we observed on pulse oximetry for the transition from normoxia to 20% CO<sub>2</sub>. Elevated heart rates may also result from activation of peripheral chemoreceptors<sup>41</sup> and sympathetic neural activation via increased plasma levels of both norepinephrine and epinephrine<sup>42,43</sup>. Therefore, the modulation of the presynaptic muscarinic inhibition of norepinephrine release, and/or increased plasma levels of catecholamine, may be the major mechanisms of the acidosis-induced increases in heart rate. In addition to affecting the chronotropic behaviour of the heart, hypercapnia has been linked to varying degrees of vasomodulation. Mild hypercapnia mediates local vasodilatation in cerebral arteries<sup>44</sup>. In the kidney, mild to moderate hypercapnia results in vasoconstriction<sup>45</sup>, and reduced




**Figure 6.** Heart rate and blood oxygen saturation response to gas challenges. Mean changes in pulse oximeter measured blood oxygen saturation and heart rate for different gas challenge regimes averaged across all animals ( $N = 4$  per group) and standard error are shown for the liver, kidney cortex, and paraspinal muscle. Exception is 2%  $\text{CO}_2$ , which was studied in a single animal. Significant differences from baseline challenges are indicated (\* $P < 0.05$ ).


perfusion at levels above 7%  $\text{CO}_2$  has been linked to activation of the renin-angiotensin system<sup>46,47</sup>. In the liver, hypercapnia below 7%  $\text{CO}_2$  has been linked to an increase in total liver blood flow via vasodilatation of mesenteric vascular system<sup>48,49</sup>, whereas an increase in  $\text{CO}_2$  above these levels increases vascular resistance and reduces total liver blood flow<sup>50</sup>. In our study, we observed similar response patterns. Mild hypercapnia at 2%  $\text{CO}_2$  resulted in a modest increase in  $T_1$  (~11%). Severe hypercapnia (20%  $\text{CO}_2$ ) exacerbated this response, resulting in a  $T_1$  increase of 45% in the kidney cortex. This  $T_1$  increase predominantly reflects a reduced microvascular volume due to vasoconstriction, since the amount of blood-pool agent in the microvasculature is the principal contributor to  $T_1$  relaxation time. Laser Doppler perfusion experiments were in agreement with MRI, showing increased perfusion for mild hypercapnia and decreased perfusion for extreme hypercapnia.

Hypoxia-mediated vasomodulation is much less characterized compared to hypercapnia. Systemic hypoxia is known to stimulate peripheral chemoreceptors that results in increased sympathetic outflow<sup>51</sup> and vasoconstriction in the renal, splanchnic, liver, and skeletal muscle vascular beds<sup>52–55</sup>. Furthermore, hypoxic stimulation of carotid chemoreceptors during controlled ventilation has negative sympathetically mediated chronotropic and inotropic effects that result in bradycardia<sup>56,57</sup>. In the present study, hypoxia reduced heart rate by 19%, consistent with expected physiological response. Also consistent with expected vasoconstriction is increased  $T_1$  observed in the kidney, liver, and the paraspinal muscle, which was confirmed by laser Doppler measurement. One interesting observation in our study was increased signal in the kidney cortex when transitioning from hypercapnic baselines to hypoxia. This differential response to hypoxia may be attributed to its biphasic behaviour wherein it mediates the release of endogenous vasodilator that counters the vasoconstrictor effect of increased sympathetic activity<sup>58,59</sup>.

The final gas challenge examined in this study was hypercapnic hypoxia. This stimulus produced the greatest increase in heart rate (30%), the largest increase in  $T_1$  relaxation time, and the largest decrease on laser Doppler perfusion measurements. Hypercapnic hypoxia-mediated elevation in heart rate has been attributed to elevated plasma catecholamine levels in response to the gas challenge<sup>60</sup>. The  $T_1$  signal reduction (or increased  $T_1$ ) observed is indicative of reduced microvascular volume, which was confirmed on laser Doppler perfusion measurements. Literature attributes this vasoconstriction to increased renal sympathetic nerve activity<sup>61,62</sup> and increased muscle sympathetic nerve activity<sup>63</sup>. The only literature inconsistency is a study by Davidson *et al.*<sup>60</sup>, who reported increased hepatic blood flow in response to hypercapnic hypoxia. In contrast, we observed reduced liver perfusion, perhaps because we employed a higher level of hypercapnic hypoxia (20%  $\text{CO}_2$  + 12%  $\text{O}_2$ ) compared to Davidson *et al.* (12%  $\text{CO}_2$  + 10%  $\text{O}_2$ ).



**Figure 7.** Laser Doppler perfusion response to gas challenges. Mean changes in blood perfusion units in the liver and kidney cortex for different gas challenge regimes averaged across all animals ( $N = 5$  per group) and standard error are shown for the liver and kidney cortex. Exceptions are 5% CO<sub>2</sub> and 12% O<sub>2</sub>, which were studied in a single animal. Significant differences from baseline challenges are indicated ( $*P < 0.05$ ).



**Figure 8.** Real-time tissue perfusion response in the liver and kidney cortex. Dynamic laser Doppler perfusion recordings are shown for the following gas sequence: normoxia → hypercapnia (20% CO<sub>2</sub>) → hypercapnic hypoxia (20% CO<sub>2</sub> + 12% O<sub>2</sub>) → hypercapnia (5% CO<sub>2</sub>). Units are in relative blood perfusion units (BPU).

In addition to developing a new non-invasive technique to measure modulation of microvessel tone dynamically, a secondary objective of this study was to investigate what sequences of gas challenges could effectively assess microvascular function or dysfunction. Not only must we be able to increase or decrease microvascular volume and then return it to original baseline levels, but we must ensure that the order of gas challenges does not inhibit dynamic response. For instance, Zanzinger *et al.*<sup>64</sup> showed that nitric oxide, one of the main mediators of hypercapnia-mediated vasodilation, actually inhibits sympathetic vasoconstriction. We also observed this phenomenon, where beginning the protocol with mild hypercapnia at 2% or 5% CO<sub>2</sub> blunted vasoconstriction on subsequent hypercapnic and/or hypoxia stimuli (Fig. 4). The ideal gas challenge protocol is one that begins with hypercapnia or hypercapnic hypoxia to produce substantial vasodilation, ending with mild hypercapnia to mediate vasodilation (see Figs 2 and 8).



In summary, we have shown that transitioning from normal air to extreme hypercapnia (20% CO<sub>2</sub>) or hypercapnic hypoxia (20% CO<sub>2</sub> + 12% O<sub>2</sub>) produced the greatest reduction in perfusion and T<sub>1</sub>-weighted signal (and corresponding increase in T<sub>1</sub> relaxation time). Since heart rate was elevated at the same time, reduced perfusion arose from vasoconstriction and not from reduced cardiac output, and lowered signal on MRI reflected a smaller microvascular volume. Further transitioning from hypercapnia to hypoxia did not necessarily bring about further vasoconstriction in all tissue types: while reduced perfusion was measured in both liver and kidney cortex on laser Doppler, MRI indicated decreased signal in liver but increased signal in kidney. This discrepancy may be due to poor whole organ resolution of the laser Doppler technique (more on this point later), because the renal MR response suggestive of vasodilation is supported by literature that shows hypoxia results in adenosine-mediated vasodilatation in the renal efferent arterioles, which overrides vasoconstriction mediated by sympathetic nerve response to peripheral chemoreceptor stimulation<sup>51, 65</sup>. Finally, transitioning from hypercapnia or hypercapnic hypoxia to mild hypercapnia significantly increased perfusion and T<sub>1</sub>-weighted signal in the kidney cortex, with little change in other organs. Since heart rate lowered at the same time, renal perfusion increase was a result of active vasodilatation. In reversing vasoconstriction, we noted that mild hypercapnia following an isocapnic hypoxic challenge had minimal vasodilatory effect.

The choice of contrast agent and validation tool (i.e. laser Doppler) deserves further discussion. It should be emphasized that our method for measuring microvessel modulation dynamics does not depend strictly on the use of gadofosveset, which may have limited clinical utility going forward since its recent removal from the European and U.S. market. In fact, any contrast agent that provides stable, long-life blood-pool characteristics would be appropriate, and this new application should be convincing incentive for the development and marketing of blood-pool agents in general. An alternative agent that can be used is gadobenate dimeglumine (MultiHance, Bracco Diagnostic, Milano, Italy), which also has partial albumin binding characteristics and has been shown to produce similar images as gadofosveset<sup>66, 67</sup>. The choice of laser Doppler for gold-standard perfusion measurement to validate MRI was motivated by its real-time acquisition capability and minimal invasiveness. However, as it provides only point-of-source measurements, laser Doppler cannot offer whole-organ assessment of microvascular response as can our MRI technique. Furthermore, we recognize that even this ideal validation tool is a perfusion, or blood flow, technique, and is not identical to our blood volume-sensitized MRI method. For instance, perfusion can change despite no change in blood volume if the perfusion pressure is altered.

Lastly, we would like to emphasize the importance of this contribution in its proper context. The technology presented herein provides a “real-time” approach to quantitatively assess microvascular physiological response to stress. The stressor applied, being a gas stimulus, induces a fairly rapid response time on the order of minutes, thereby necessitating measurements on the same temporal scale. With a view towards clinical translation, dynamic 3D T<sub>1</sub>-weighted acquisitions are ideal for rapidly capturing these microvascular changes with high spatial resolution. Also important to note is that we have used the term “blood volume” to indicate we sensitized our measurements to blood volume rather than blood flow, but we are not measuring absolute blood volume. Converting measured T<sub>1</sub> to absolute blood volume would require knowledge of the hematocrit, which may change due to gas manipulation, and the potential effects of proton exchange. A final point to note is that the proposed technique is not optimized for studying gas responses in detail. There is inevitably background contrast elimination, and we determined that the first 40 minutes post-contrast was adequately “stable” to traverse the full vasoconstriction-vasodilation regime. However, because of the background drift, one should not compare response at the end of 40 minutes to much earlier timepoints in absolute terms. Instead, one should focus on the rapid T<sub>1</sub> changes between successive gas challenges, which allows us to safely disregard effects from much more slowly varying background drifts from contrast elimination. The gas stimulus protocol shown in Fig. 2 was designed to elicit a measurable and reproducible response within the practical limits imposed by the contrast agent. For an in-depth investigation on the order of gas delivery, the effect of prolonged gas stimuli, and lag times upon return to room air, we refer the reader to our previous work<sup>24</sup>.

## Conclusions

We have presented a novel non-invasive method based on MRI to monitor the dynamics of microvessel response *in vivo*. To our knowledge, this is the only non-invasive technique reported to date that allows assessment of the capacity for vasomodulation in the microvascular bed in a volume of deep tissue. This technique enables much higher spatial resolution than arterial spin labeling approaches and circumvents specificity issues related to iron-oxide based methods for blood volume measurements. We have also developed an optimized gas challenge protocol that allows accurate assessment of microvascular tone control by inducing first vasoconstriction (an active process) and then vasodilatation (a relaxation process). The concepts presented herein for imaging assessment of dynamic vasomotion can be extended to other imaging modalities and will unlock the power to explore functional dynamics in a variety of disease settings.

## References

- Schelbert, H. R. *et al.* Intravenous myocardial imaging performed serially early and late after acute myocardial infarction. *Eur J Nucl Med* **2**, 75–83 (1977).
- Ostergaard, L. *et al.* The role of the cerebral capillaries in acute ischemic stroke: the extended penumbra model. *J Cereb Blood Flow Metab* **33**, 635–648, doi:10.1038/jcbfm.2013.18 (2013).
- Farkas, E. & Luiten, P. G. Cerebral microvascular pathology in aging and Alzheimer's disease. *Prog Neurobiol* **64**, 575–611 (2001).
- Williams, M. A. *et al.* Retinal microvascular network attenuation in Alzheimer's disease. *Alzheimers Dement (Amst)* **1**, 229–235, doi:10.1016/j.dadm.2015.04.001 (2015).
- Groen, B. B. *et al.* Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes. *J Appl Physiol* (1985) **116**, 998–1005, doi:10.1152/jappphysiol.00919.2013 (2014).
- Johnson, P. C., Brendel, K. & Meezan, E. Thickened cerebral cortical capillary basement membranes in diabetics. *Arch Pathol Lab Med* **106**, 214–217 (1982).

7. Yemisci, M. *et al.* Pericyte contraction induced by oxidative-nitrate stress impairs capillary reflow despite successful opening of an occluded cerebral artery. *Nat Med* **15**, 1031–1037, doi:[10.1038/nm.2022](https://doi.org/10.1038/nm.2022) (2009).
8. Reske, S. N. *et al.* Assessment of regional myocardial uptake and metabolism of omega-(p-123I-phenyl) pentadecanoic acid with serial single-photon emission tomography. *Nuklearmedizin* **21**, 249–253 (1982).
9. Nevieri, R. *et al.* Skeletal muscle microvascular blood flow and oxygen transport in patients with severe sepsis. *Am J Respir Crit Care Med* **153**, 191–195, doi:[10.1164/ajrccm.153.1.8542115](https://doi.org/10.1164/ajrccm.153.1.8542115) (1996).
10. Young, J. D. & Cameron, E. M. Dynamics of skin blood flow in human sepsis. *Intensive Care Med* **21**, 669–674 (1995).
11. Franzeck, U. K., Bollinger, A., Huch, R. & Huch, A. Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. *Circulation* **70**, 806–811 (1984).
12. Jorneskog, G. *et al.* Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. *Diabetes Care* **28**, 1495–1497 (2005).
13. Abularrage, C. J. *et al.* Evaluation of the microcirculation in vascular disease. *J Vasc Surg* **42**, 574–581, doi:[10.1016/j.jvs.2005.05.019](https://doi.org/10.1016/j.jvs.2005.05.019) (2005).
14. Lerman, L. O. & Rodriguez-Porcel, M. Functional assessment of the circulation of the single kidney. *Hypertension* **38**, 625–629 (2001).
15. Tello, R. *et al.* MR perfusion imaging of the kidney pre- and post-dipyridamole stress. *J Magn Reson Imaging* **6**, 460–464 (1996).
16. Elkayam, U. *et al.* Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. *J Am Coll Cardiol* **28**, 176–182 (1996).
17. Walker, H. A., Jackson, G., Ritter, J. M. & Chowienczyk, P. J. Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement. *Br J Clin Pharmacol* **51**, 225–229 (2001).
18. Benjamin, N. *et al.* Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. *J Physiol* **412**, 543–555 (1989).
19. Johnston, D. L., Daley, J. R., Hodge, D. O., Hopfenspirger, M. R. & Gibbons, R. J. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2,000 patients. *Mayo Clin Proc* **70**, 331–336, doi:[10.1016/S0025-6196\(11\)63411-3](https://doi.org/10.1016/S0025-6196(11)63411-3) (1995).
20. Spano, V. R. *et al.* CO<sub>2</sub> blood oxygen level-dependent MR mapping of cerebrovascular reserve in a clinical population: safety, tolerability, and technical feasibility. *Radiology* **266**, 592–598, doi:[10.1148/radiol.12112795](https://doi.org/10.1148/radiol.12112795) (2013).
21. Steinback, C. D., Salzer, D., Medeiros, P. J., Kowalchuk, J. & Shoemaker, J. K. Hypercapnic vs. hypoxic control of cardiovascular, cardiovagal, and sympathetic function. *Am J Physiol Regul Integr Comp Physiol* **296**, R402–410, doi:[10.1152/ajpregu.90772.2008](https://doi.org/10.1152/ajpregu.90772.2008) (2009).
22. Desplanches, D. *et al.* Effects of training in normoxia and normobaric hypoxia on human muscle ultrastructure. *Pflügers Arch* **425**, 263–267 (1993).
23. Messonnier, L., Geysant, A., Hintzy, F. & Lacour, J. R. Effects of training in normoxia and normobaric hypoxia on time to exhaustion at the maximum rate of oxygen uptake. *Eur J Appl Physiol* **92**, 470–476, doi:[10.1007/s00421-004-1117-2](https://doi.org/10.1007/s00421-004-1117-2) (2004).
24. Ganesh, T., Estrada, M., Duffin, J. & Cheng, H. L. T<sub>2</sub>\* and T<sub>1</sub> assessment of abdominal tissue response to graded hypoxia and hypercapnia using a controlled gas mixing circuit for small animals. *J Magn Reson Imaging* **44**, 305–316, doi:[10.1002/jmri.25169](https://doi.org/10.1002/jmri.25169) (2016).
25. Barash, H. *et al.* Functional MR imaging during hypercapnia and hyperoxia: noninvasive tool for monitoring changes in liver perfusion and hemodynamics in a rat model. *Radiology* **243**, 727–735, doi:[10.1148/radiol.2433060433](https://doi.org/10.1148/radiol.2433060433) (2007).
26. Winter, J. D., Estrada, M. & Cheng, H. L. Normal tissue quantitative T<sub>1</sub> and T<sub>2</sub>\* MRI relaxation time responses to hypercapnic and hyperoxic gases. *Acad Radiol* **18**, 1159–1167, doi:[10.1016/j.acra.2011.04.016](https://doi.org/10.1016/j.acra.2011.04.016) (2011).
27. Cheng, H. L. Effect of hyperoxia and hypercapnia on tissue oxygen and perfusion response in the normal liver and kidney. *PLoS One* **7**, e40485, doi:[10.1371/journal.pone.0040485](https://doi.org/10.1371/journal.pone.0040485) (2012).
28. Milman, Z. *et al.* Hemodynamic response magnetic resonance imaging: application for renal hemodynamic characterization. *Nephrol Dial Transplant* **28**, 1150–1156, doi:[10.1093/ndt/gfs541](https://doi.org/10.1093/ndt/gfs541) (2013).
29. Cheng, H. L. & Wright, G. A. Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. *Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine* **55**, 566–574 (2006).
30. Tofts, P. S. *et al.* Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. *J Magn Reson Imaging* **10**, 223–232 (1999).
31. Ezzeddine, M. A. *et al.* CT angiography with whole brain perfused blood volume imaging: added clinical value in the assessment of acute stroke. *Stroke* **33**, 959–966 (2002).
32. Levy, B. I. *et al.* Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. *Circulation* **118**, 968–976, doi:[10.1161/CIRCULATIONAHA.107.763730](https://doi.org/10.1161/CIRCULATIONAHA.107.763730) (2008).
33. Daghini, E. *et al.* Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT. *Radiology* **243**, 405–412, doi:[10.1148/radiol.2432060655](https://doi.org/10.1148/radiol.2432060655) (2007).
34. Kulshreshtha, A. *et al.* Endothelial Dysfunction is Associated with Occult Coronary Artery Disease Detected by Positron Emission Tomography. *IJC Metab Endocr* **4**, 28–32, doi:[10.1016/j.ijcme.2014.07.004](https://doi.org/10.1016/j.ijcme.2014.07.004) (2014).
35. Wei, K. *et al.* Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. *Circulation* **97**, 473–483 (1998).
36. Krivokapich, J. *et al.* 13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. *Circulation* **80**, 1328–1337 (1989).
37. Abramovitch, R., Frenkiel, D. & Neeman, M. Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. *Magn Reson Med* **39**, 813–824 (1998).
38. Hindel, S. *et al.* Validation of Blood Volume Fraction Quantification with 3D Gradient Echo Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Porcine Skeletal Muscle. *PLoS One* **12**, e0170841, doi:[10.1371/journal.pone.0170841](https://doi.org/10.1371/journal.pone.0170841) (2017).
39. Walley, K. R., Lewis, T. H. & Wood, L. D. Acute respiratory acidosis decreases left ventricular contractility but increases cardiac output in dogs. *Circ Res* **67**, 628–635 (1990).
40. Stengl, M. *et al.* Effects of clinically relevant acute hypercapnic and metabolic acidosis on the cardiovascular system: an experimental porcine study. *Crit Care* **17**, R303, doi:[10.1186/cc13173](https://doi.org/10.1186/cc13173) (2013).
41. Shoemaker, J. K., Vovk, A. & Cunningham, D. A. Peripheral chemoreceptor contributions to sympathetic and cardiovascular responses during hypercapnia. *Can J Physiol Pharmacol* **80**, 1136–1144 (2002).
42. Brofman, J. D., Leff, A. R., Munoz, N. M., Kirchoff, C. & White, S. R. Sympathetic secretory response to hypercapnic acidosis in swine. *J Appl Physiol* (1985) **69**, 710–717 (1990).
43. Haunstetter, A., Schulze Icking, B., Backs, J., Kruger, C. & Haass, M. Differential effects of acidosis, high potassium concentrations, and metabolic inhibition on noradrenaline release and its presynaptic muscarinic regulation. *Pharmacol Res* **45**, 221–228, doi:[10.1006/phrs.2001.0943](https://doi.org/10.1006/phrs.2001.0943) (2002).
44. Hoiland, R. L. & Ainslie, P. N. CrossTalk proposal: The middle cerebral artery diameter does change during alterations in arterial blood gases and blood pressure. *J Physiol* **594**, 4073–4075, doi:[10.1113/JP271981](https://doi.org/10.1113/JP271981) (2016).
45. In *Seldin and Giebisch's The Kidney: Physiology & Pathophysiology 1-2* (eds R. J. Alpern & S. C. Hebert) 1739 (Academic Press, 2007).
46. Hemlin, M. *et al.* The effects of hypoxia and hypercapnia on renal and heart function, haemodynamics and plasma hormone levels in stable COPD patients. *Clin Respir J* **1**, 80–90, doi:[10.1111/j.1752-699X.2007.00031.x](https://doi.org/10.1111/j.1752-699X.2007.00031.x) (2007).

47. Rose, C. E. Jr., Kimmel, D. P., Godine, R. L. Jr., Kaiser, D. L. & Carey, R. M. Synergistic effects of acute hypoxemia and hypercapnic acidosis in conscious dogs. Renal dysfunction and activation of the renin-angiotensin system. *Circ Res* **53**, 202–213 (1983).
48. Fujita, Y., Sakai, T., Ohsumi, A. & Takaori, M. Effects of hypocapnia and hypercapnia on splanchnic circulation and hepatic function in the beagle. *Anesth Analg* **69**, 152–157 (1989).
49. Winterdahl, M. *et al.* Hepatic blood perfusion estimated by dynamic contrast-enhanced computed tomography in pigs: limitations of the slope method. *Invest Radiol* **47**, 588–595, doi:10.1097/RLI.0b013e318260abb3 (2012).
50. Epstein, R. M. *et al.* The effect of hypercapnia on estimated hepatic blood flow, circulating splanchnic blood volume, and hepatic sulfobromophthalein clearance during general anesthesia in man. *J Clin Invest* **40**, 592–598, doi:10.1172/JCI104288 (1961).
51. Paton, J. F. *et al.* Revelations about carotid body function through its pathological role in resistant hypertension. *Curr Hypertens Rep* **15**, 273–280, doi:10.1007/s11906-013-0366-z (2013).
52. Marshall, J. M. & Metcalfe, J. D. Analysis of factors that contribute to cardiovascular changes induced in the cat by graded levels of systemic hypoxia. *J Physiol* **412**, 429–448 (1989).
53. Dutton, R., Levitzky, M. & Berkman, R. Carbon dioxide and liver blood flow. *Bull Eur Physiopathol Respir* **12**, 265–273 (1976).
54. Yang, W. *et al.* The effect of graded systemic hypoxaemia on hepatic tissue oxygenation. *Adv Exp Med Biol* **540**, 317–323 (2003).
55. Hudson, S., Johnson, C. D. & Marshall, J. M. Changes in muscle sympathetic nerve activity and vascular responses evoked in the spinotrapezius muscle of the rat by systemic hypoxia. *J Physiol* **589**, 2401–2414, doi:10.1113/jphysiol.2010.201814 (2011).
56. James, J. E. & Daly Mde, B. Cardiovascular responses in apnoeic asphyxia: role of arterial chemoreceptors and the modification of their effects by a pulmonary vagal inflation reflex. *J Physiol* **201**, 87–104 (1969).
57. Greenwood, P. V., Hainsworth, R., Karim, F., Morrison, G. W. & Sofola, O. A. The effect of stimulation of carotid chemoreceptors on the inotropic state of the left ventricle [proceedings]. *J Physiol* **266**, 47P–48P (1977).
58. Weisbrod, C. J., Minson, C. T., Joyner, M. J. & Halliwill, J. R. Effects of regional phenolamine on hypoxic vasodilatation in healthy humans. *J Physiol* **537**, 613–621 (2001).
59. Tamisier, R., Norman, D., Anand, A., Choi, Y. & Weiss, J. W. Evidence of sustained forearm vasodilatation after brief isocapnic hypoxia. *J Appl Physiol* (1985) **96**, 1782–1787, doi:10.1152/jappphysiol.01241.2003 (2004).
60. Davidson, D., Stalcup, S. A. & Mellins, R. B. Systemic hemodynamics affecting cardiac output during hypocapnic and hypercapnic hypoxia. *J Appl Physiol* (1985) **60**, 1230–1236 (1986).
61. Hirakawa, H., Nakamura, T. & Hayashida, Y. Effect of carbon dioxide on autonomic cardiovascular responses to systemic hypoxia in conscious rats. *Am J Physiol* **273**, R747–754 (1997).
62. Sharkey, R. A., Mulloy, E. M. & O'Neill, S. J. Acute effects of hypoxaemia, hyperoxaemia and hypercapnia on renal blood flow in normal and renal transplant subjects. *Eur Respir J* **12**, 653–657 (1998).
63. Morgan, B. J., Crabtree, D. C., Palta, M. & Skatrud, J. B. Combined hypoxia and hypercapnia evokes long-lasting sympathetic activation in humans. *J Appl Physiol* (1985) **79**, 205–213 (1995).
64. Zanzinger, J., Czachurski, J. & Seller, H. Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide *in vivo*. *Circ Res* **75**, 1073–1077 (1994).
65. Neylon, M. & Marshall, J. M. The role of adenosine in the respiratory and cardiovascular response to systemic hypoxia in the rat. *J Physiol* **440**, 529–545 (1991).
66. Camren, G. P. *et al.* A comparison between gadofosveset trisodium and gadobenate dimeglumine for steady state MRA of the thoracic vasculature. *Biomed Res Int* **2014**, 625614, doi:10.1155/2014/625614 (2014).
67. Frydrychowicz, A. *et al.* Comparison of gadofosveset trisodium and gadobenate dimeglumine during time-resolved thoracic MR angiography at 3T. *Acad Radiol* **17**, 1394–1400, doi:10.1016/j.acra.2010.05.022 (2010).

## Acknowledgements

T.G. is supported by an NSERC doctoral scholarship (PGS D2). H.-L.M.C. is funded by the Heart and Stroke Foundation of Canada (#000223), the Natural Sciences and Engineering Research Council of Canada (#355795), and the Canada Foundation for Innovation/Ontario Research Fund (#34038).

## Author Contributions

Hai-Ling Cheng contributed to: (i) conception of study, overall direction, and design of experiments, (ii) design of MR acquisition protocol, (iii) acquisition of data, (iv) analysis and interpretation of data, (v) drafting and revising the article, and (vi) providing final approval of the version submitted. Tameshwar Ganesh contributed to: (i) direction and design of experiments, (ii) design of the gas challenge protocol, (iii) acquisition of data, (iv) analysis and interpretation of data, (v) drafting and revising the article, and (vi) providing final approval of the version submitted. Marvin Estrada contributed to: (i) animal handling, including intubation and monitoring animal immediately post-intubation, and (ii) providing final approval of the version submitted. Herman Yeger contributed to: (i) discussion on initial conception of study, and (ii) providing final approval of the version submitted. James Duffin contributed to: (i) discussion on the design of the gas challenge protocol, and (ii) providing final approval of the version submitted.

## Additional Information

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017